The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.
Experts Discuss Immunotherapy's Potential in Neuro-OncologyNovember 17th 2014
Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.
Dr. Stupp Discusses NovoTTF With Temozolomide in GlioblastomaNovember 16th 2014
Roger Stupp, MD, Professor of Oncology, University of ZÃ¼rich; Chairman, Department of Oncology and Cancer Center, University of ZÃ¼rich Hospital, ZÃ¼rich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).
Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBMNovember 16th 2014
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).
Dr. van den Bent Discusses Bevacizumab Plus Lomustine in Recurrent GlioblastomaNovember 15th 2014
Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.
Dr. Reardon Discusses Rindopepimut Plus Bevacizumab in GlioblastomaNovember 15th 2014
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.
Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade GliomasNovember 14th 2014
Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.
Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma TherapyAugust 29th 2014
Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.
Evidence Builds for Electric Field Therapy in Recurrent GBMAugust 19th 2014
A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression
The Role of Radiation in the Management of Brain MetastasesMarch 6th 2014
In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Dr. Gilbert Describes Ongoing RTOG 0825 Trial AnalysesJune 3rd 2013
Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.